以下，列舉本發明之實施形態，對本發明進一步詳細地進行說明，但本發明並不限定於該等。以下，於本發明中，將包含鳶尾黃素及鳶尾黃素糖苷之組合物、及包含該等之減少脂肪用組合物、抗肥胖用組合物、促進組織分化用組合物、促進脂肪分解用組合物、用於提高角質層水分量、提高皮膚彈力或抑制皮膚水分蒸散之組合物、改善肝功能用組合物統稱為「本發明之組合物」。 (鳶尾黃素) 本發明中所使用之鳶尾黃素係由分子式C16
H12
O6
表示，亦有稱為5,7-二羥基-3-(4-羥基苯基)-6-甲氧基-4H-1-苯并吡喃-4-酮(5,7-Dihydroxy-3-(4-hydroxyphenyl)-6-methoxy-4H-1-benzopyran-4-one)或者6-
甲氧基-5,7-二羥基-3-(4-羥基苯基)-4H-1-苯并吡喃-4-酮(6-
Methoxy-5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one)之情形。以下亦將鳶尾黃素記載為TGE。鳶尾黃素之化學式如下所示。 [化1](鳶尾黃素糖苷) 作為鳶尾黃素糖苷(以下亦稱為TGE糖苷)，係將上述TGE中1處或2處之氫取代為糖而成者，例如可列舉：鍵結選自葡萄糖、木糖、山梨糖、半乳糖、洋芹糖、鼠李糖之1種或2種以上之糖而成者。就提高促進組織分化、促進脂肪分解、改善肝功能、改善膚質等本發明之效果之觀點而言，較佳為於TGE上鍵結選自葡萄糖、木糖之1種或2種以上之糖而成者。於糖苷中，該等糖通常與TGE之4位及/或7位之羥基鍵結，就更確實地獲得上述效果之方面或糖苷之獲取容易性之方面而言，較佳為與7位之羥基鍵結者。TGE糖苷中之糖之數量(亦稱為糖之鍵結數)例如可列舉1個以上，就提高上述效果之觀點而言，糖之鍵結數較佳為1個〜3個，更佳為1〜2個。此處所謂糖之數量，係指單糖單元之數量。作為TGE糖苷，可僅使用1種，但較佳為組合2種以上。TGE及TGE糖苷於本發明之組合物中，可為有機合成品，亦可從植物等萃取。TGE及TGE糖苷可為粉末狀等固體狀，亦可為溶解於水或有機溶劑中之狀態。TGE及TGE糖苷亦可僅以該等之混合物之形式存在，亦可為溶解、分散或混合至其他物質中之狀態。 作為於TGE上鍵結1個糖而成之糖苷，例如可列舉：鳶尾苷(Tectoridin)、鳶尾苷4'-葡糖苷。又，作為於TGE上鍵結2個糖而成之糖苷，可列舉鳶尾黃素-7-O-木糖葡萄糖苷(tectorigenin-7-O-xylosylglucoside)。此處，所謂於TGE上鍵結n個糖，可鍵結n個糖之連結體，亦可鍵結於鳶尾苷之不同部位之糖之合計數為n個。所謂鳶尾苷，係於TGE之7位上鍵結1個葡萄糖而成之糖苷，例如亦表示為鳶尾黃素7-O-β-D-葡萄糖苷或7-(β-D-吡喃葡萄糖氧基)-4',5-二羥基-6-甲氧基異黃酮(7-(β-D-Glucopyranosyloxy)-4',5-dihydroxy-6-methoxyisoflavone)等。所謂鳶尾苷4'-葡糖苷，係於TGE之4位上鍵結1個葡萄糖而成之糖苷，例如亦稱為鳶尾黃素4'-O-β-D-葡萄糖苷或3-[4-(β-D-吡喃葡萄糖氧基)苯基]-5,7-二羥基-6-甲氧基-4H-1-苯并吡喃-4-酮(3-[4-(β-D-Glucopyranosyloxy)phenyl]-5,7-dihydroxy-6-methoxy-4H-1-benzopyran-4-one)等。鳶尾黃素-7-O-木糖葡萄糖苷係於TGE之7位上鍵結1個葡萄糖，且於該葡萄糖上進而鍵結木糖而成之糖苷，例如亦稱為6''-O-木糖鳶尾苷(6''-O-Xylosyltectoridin)。例如，鳶尾苷(以下亦稱為TD)具有以下化學式之結構。 [化2]又，例如鳶尾黃素-7-O-木糖葡萄糖苷(以下亦稱為TGXG)具有以下化學式之結構。式中，Glu係葡萄糖基，Xyl係木糖基。 [化3]於本發明中，就上述效果優異之方面而言，較佳為TGE糖苷包含於TGE上鍵結1個糖而成之糖苷及於TGE上鍵結2個糖而成之配合體。於TGE糖苷包含於TGE上鍵結1個糖而成之糖苷及於TGE上鍵結2個糖而成之配合體之情形時，於TGE上鍵結1個糖而成之糖苷與於TGE上鍵結2個糖而成之糖苷之質量比較佳為前者：後者為1：0.01以上且7.5以下。該質量比為1：0.01以上有如下優點：能夠獲得本發明之較高作用，並且將TD等之於TGE上鍵結1個糖而成之糖苷之量限制為一定量。又，藉由使該質量比為1：7.5以下，能夠進一步提高上述效果。就該等觀點而言，於TGE上鍵結1個糖而成之糖苷與於TGE上鍵結2個糖而成之糖苷之量比，較佳為前者：後者為1：0.01以上且5以下，尤佳為1：0.1以上且2.5以下。 又，作為TGE糖苷，就更確實地提高上述效果之觀點、及糖苷之獲取容易性等觀點而言，亦較佳為包含TD作為於TGE上鍵結1個糖而成之糖苷，並且包含TGXG作為於TGE上鍵結2個糖而成之配合體，且TD與TGXG之調配比為上述較佳比率1：0.01以上且7.5以下。TD與TGXG之調配比尤佳為1：0.01以上且5以下，尤佳為1：0.1以上且2.5以下。 於本發明中，關於TGE與TGE糖苷之量比，並無特別限制，於將TGE與TGE糖苷以特定比率組合之情形時，能夠獲得尤其優異之效果。於TGE糖苷相對於TGE之質量比為1：10以上之情形時，促進脂肪分解之作用或改善肝功能之作用飛躍性地提高。進而，就使促進脂肪分解之作用或改善肝功能之效果變得尤其優異之觀點而言，TGE與TGR糖苷之質量比更佳為1：13以上，進而較佳為1：16以上，尤佳為1：18以上。又，發現就使減少脂肪、抗肥胖、促進組織分化、提高角質層水分量、提高皮膚彈力或抑制皮膚水分蒸散之效果變得尤其優異之觀點而言，亦較佳為將TGE與TGE糖苷之質量比設為上述特定比率。本發明之組合物可將所合成之鳶尾黃素及鳶尾黃素糖苷組合而調配，亦可為鳶尾科之射干(Belamcanda chinensis)或豆科之葛(粉葛(Pueraria thomsonii)、野葛(Pueraria lobata)、葛藤(Pueraria thunbergiana)等)之花部等植物之萃取物。作為植物之萃取物，尤佳為豆科之葛之花部之萃取物。又，可於植物之萃取物中添加有機合成品而製備，亦可將源自複數種植物之萃取物組合而製備，亦可將有機合成品組合而製備。 關於TGE與TGE糖苷之質量比，就防止由TGE糖苷引起之皮膚炎、嘔吐、下痢、腸胃炎等副作用之觀點而言，較佳為將TGE糖苷之量設為一定以下。就該觀點而言，較佳為將TGE與TGE糖苷之質量比設為較佳為1：500以下、更佳為1：250以下、進而較佳為1：100以下、尤佳為1：50以下。 又，就提高上述效果之觀點而言，作為TGE與TGE糖苷之質量比、以及於TGE上鍵結1個糖而成之糖苷與於TGE上鍵結2個糖而成之糖苷之質量比之組合，較佳為TGE與TGE糖苷之質量比為1：10以上，且於TGE上鍵結1個糖而成之糖苷與於TGE上鍵結2個糖而成之糖苷之質量比為1：0.01以上且7.5以下。該組合中質量比或TGE糖苷之較佳例已如上所述。 本發明之組合物中之TGE及TGE糖苷之量之測定能夠利用HPLC(High performance liquid chromatography，高效液相層析)法定量地或定性地確認。用以供於HPLC之試樣係藉由適當去除雜質或調整濃度等公知之方法製備。 本發明之組合物只要以特定比率包含TGE及TGE糖苷，則會發揮尤其優異之效果，就更進一步提高減少脂肪、抗肥胖、促進組織分化、促進脂肪分解、提高角質層水分量、提高皮膚彈力、抑制皮膚水分蒸散或改善肝功能之效果之觀點而言，尤佳為包含賦形劑。作為賦形劑，例如可列舉：還原麥芽糖、還原帕拉金糖(reduced palatinose)、糊精、難消化性糊精、纖維素、聚葡萄糖、澱粉、環糊精、乳糖、葡萄糖、砂糖、還原麥芽糖、麥芽糖、山梨糖醇、赤蘚糖醇、木糖醇、乳糖醇、甘露糖醇。其中，就提高本發明之效果之觀點而言，尤佳為還原麥芽糖、還原帕拉金糖、糊精、難消化性糊精、纖維素、聚葡萄糖。 又，就更進一步提高減少脂肪、抗肥胖、促進組織分化、促進脂肪分解、提高角質層水分量、提高皮膚彈力、抑制皮膚水分蒸散或改善肝功能之效果之觀點而言，本發明之組合物尤佳為包含油脂類。作為油脂類，例如可列舉：紅花油、橄欖油、菜籽油、棕櫚油、芝麻油、大豆油、紫蘇油、亞麻仁油、洋甘菊油、米糠油、小麥胚芽油、牛油樹油脂、蓖麻油、葵花籽油、澳洲胡桃油、糙米胚芽油、山茶油、玉米油、魚油、椰子油、長鏈/中長鏈/短鏈脂肪酸甘油三酯、二醯基甘油酯、以及該等油脂類之氫化物等。其中，就提高本發明之效果之觀點而言，尤佳為紅花油、橄欖油、菜籽油、棕櫚油、芝麻油、大豆油。 本發明之組合物除上述以外，亦可於無損本發明之效果之範圍內含有通常所使用之其他成分。作為此種成分，可列舉：各種結合劑、光澤劑、潤滑劑、穩定劑、稀釋劑、增量劑、增黏劑、乳化劑、抗氧化劑、pH值調整劑、著色料、香料、添加劑等。其他成分之含量能夠視本發明之組合物之形態等而適當地選擇。 本發明之組合物能夠用作外用或經口用。作為外用劑，只要塗抹於皮膚、頭皮等上使用，則並無特別限制，作為其形態，可列舉：軟膏劑、乳霜劑、凝膠劑、洗劑、乳液劑、敷劑、濕敷劑等皮膚外用劑、或注射劑等形態。 又，於將本發明之組合物用作經口劑之情形時，作為其形態，例如可列舉：錠劑、膠囊劑、粉末劑(再者，本發明之粉末包括顆粒、細粒)、液劑、棒狀劑、板狀劑、塊狀劑、固體狀劑、丸狀劑、膏狀劑、乳霜狀劑、膠囊錠狀劑、凝膠狀劑、咀嚼錠狀劑、條狀劑等。該等之中，就更進一步提昇提高角質層水分量、提高皮膚彈力或抑制皮膚水分蒸散之效果之觀點而言，尤佳為錠劑、膠囊劑、粉末劑或液劑之形態。以錠劑、膠囊劑、粉末劑或液劑之形態攝取本發明之組合物之情形與以膏狀或乳霜狀、凝膠狀等其他形態攝取之情形相比，能夠於提高角質層水分量、提高皮膚彈力或抑制皮膚水分蒸散方面獲得更高之效果。其原因並未明確，但認為主要原因在於：根據組合物之形態不同，對於攝取者產生之心理上之影響不同；或者根據形狀不同，TGE及TGE糖苷之體內吸收率不同。 作為將本發明之組合物用作經口劑之情形之具體例，可例示：補充品(supplement)；食品添加劑；填充至寶特瓶、罐、瓶等中之容器裝飲料；用以溶解於水(熱水)、牛奶、果汁等中飲用之即溶粉末飲料等。該等就進食時等容易簡單地飲食，又能夠提高可口性之方面而言較佳。 一般，於本發明之組合物為錠劑、膠囊劑之情形時，就更為提高由本發明帶來之上述各效果之觀點而言，較佳為於其固形物成分中，有效成分包含固形物成分總體之2.0～0.001質量%之TGE，更佳為包含1.0〜0.01質量%，進而較佳為包含0.5〜0.025質量%。又，TGE及TGE糖苷之合計量若於本發明之組合物之固形物成分中例如為0.5質量%以上、尤其是1質量%以上，則上述各效果進一步優異，故而較佳。關於作為錠劑或膠囊劑之本發明之組合物，例如可列舉醫藥品或補充品等。 於本發明之組合物為液劑之情形時，就更為提高由本發明帶來之上述各效果之觀點而言，較佳為於該液劑中，有效成分包含總體之0.00001〜0.5質量%之TGE，更佳為包含0.00005〜0.1質量%，進而較佳為包含0.0001〜0.05質量%。又，TGE及TGE糖苷之合計量若於本發明之組合物之固形物成分中例如為0.0001質量%以上、尤其是0.1質量%以上，則上述各效果進一步優異，故而較佳。關於作為液劑之本發明之組合物，可列舉容器裝飲料等。 又，於本發明之組合物為粉末劑或顆粒劑之情形時，就更為提高由本發明帶來之上述各效果之觀點而言，較佳為於其固形物成分中，有效成分包含固形物成分總體之0.0001〜2.5質量%之TGE，更佳為包含0.001〜2.0質量%，進而較佳為包含0.005～1.5質量%。又，TGE及TGE糖苷之合計量若於本發明之組合物之固形物成分中例如為0.001質量%以上、尤其是0.01質量%以上，則上述各效果進一步優異，故而較佳。關於作為粉末劑之本發明之組合物，可列舉即溶粉末飲料等。 於經口攝取本發明之組合物之情形時，關於其經口投予量，以上述TGE及TGE糖苷之乾燥物合計量計，較佳為成人每天大約5 mg以上且200 mg以下，更佳為10 mg以上且100 mg以下。又，關於本發明之組合物之1次之攝取量，較佳為以上述TGE及TGE糖苷之乾燥物合計量計，成人每天大約15 mg以上且50 mg以下。本發明之組合物能夠以1天量收容於1個容器中，或者分開收容於例如2〜3個之複數個容器中，以使1天之攝取量成為上述攝取量。 作為本發明之組合物之利用形態，具體而言，可列舉：醫藥品(包括準藥品)、化妝品、普通食品、營養功能食品、效能之標示得到特定機構認可之特定保健用食品、功能性標示食品等所謂健康食品等。 本發明之組合物之應用形態中，作為食品，例如可列舉：碳酸飲料、營養飲料、果實飲料、乳酸飲料、果昔(Smoothie)、青汁等飲料；冰淇淋、雪酪、刨冰等冷凍甜點：蕎麥麵、烏冬麵、粉絲、中華麵、即食麵等麵類；飴糖、糖果、口香糖、巧克力、模壓點心、休閒點心、餅乾、果凍、果醬、奶油、烘烤糕點、麵包等點心類；魚糕、火腿、香腸等水產、畜產加工食品；加工乳、醱酵乳、酸奶等乳製品；沙拉油、天婦羅油、人造黃油、蛋黃醬、起酥油、稠奶油、調味醬等油脂及其加工食品；醬料、醬油等調味料；咖喱、燉菜、雞肉雞蛋蓋飯、粥、雜燴、中華蓋飯、豬排蓋飯、炸蝦蓋飯、牛肉蓋飯、肉丁蓋飯、蛋包飯、關東煮、麻婆豆腐、餃子、燒賣、煎肉餅、肉丸子、各種醬料、各種湯等殺菌袋裝食品等。 本發明之組合物不僅能夠經濟且安全地經口攝取，而且根據下述實施例之記載可明確，本發明之組合物藉由含有TGE及TGE糖苷，能夠藉由攝取其而促進從橫紋肌等成肌細胞進行肌肉分化，此外，亦可促進從前成骨細胞向成骨細胞分化，從而能夠促進骨分化。又，本發明之組合物藉由含有TGE及TGE糖苷，能夠藉由攝取其而獲得優異之脂肪分解作用。例如，根據下述實施例之記載可明確，能夠藉由攝取TGE及TGE糖苷而促進分解體脂肪之酶之基因之表現，促進體脂肪分解。 進而，於本發明中，TGE及TGE糖苷有效地提高改善肝功能之作用。具體而言，根據下述實施例之記載可明確，TGE及TGE糖苷能夠提高於無血清培養基中培養之肝細胞之活性(酶活性)，該肝細胞存在各種應力成為誘因而導致容易產生細胞凋亡等問題。即，TGE及TGE糖苷抑制肝細胞之活性降低，即保護肝細胞。如上所述，TGE及TGE糖苷能夠保護肝細胞，因此防止肝細胞之損害，維持或增進肝細胞之活性而改善肝功能。尤其是期待藉由保護肝細胞免受各種應力而防止肝細胞之損傷，從而抑制肝細胞中之天冬胺酸轉胺酶(AST)、丙胺酸轉胺酶(Alanine transaminase，ALT)、γ-谷胺醯轉肽酶(γ-glutamyltransferase，γ-GTP)向血中轉移。 又，藉由攝取TGE及TGE糖苷而能夠獲得提高皮膚之角質層水分量之作用、提高皮膚彈力之作用、抑制皮膚水分蒸散之作用。該等改善膚質之作用係藉由持續地攝取本發明之組合物而顯著地表現，例如於經口攝取開始後4週以內表現，進而藉由8週之持續攝取、尤其是12週之持續攝取而顯著地表現。此處所謂持續攝取，係指持續例如於1～3天內至少攝取1次之狀態。 此種本發明之組合物能夠用作促進肌肉分化用組合物、促進肌肉形成用組合物、促進骨分化用組合物、促進骨形成用組合物、促進脂肪分解用組合物、促進脂質代謝用組合物、減少脂肪用組合物、抗肥胖用組合物、減重用組合物、美容組合物、增加皮膚水分量用組合物、抑制水分蒸散用組合物、提高肌膚彈力用組合物、改善膚質組合物等，此外，亦能夠用作基於預防或抑制肝細胞之脫離酶流出之作用、預防或抑制肝細胞損傷之作用、保護肝細胞之作用、保護或改善肝功能之作用之肝功能改善劑或肝功能改善組合物，能夠用於病毒性肝炎、藥物性肝損傷、自身免疫性肝炎、原發性膽汁性肝硬化、布加氏(Budd-Chiari)症候群等肝功能損傷之治療或預防。如上所述，本發明之組合物能夠用於防止宿醉等與飲酒相關之疾病以外之損傷。 又，本發明之組合物只要於用於促進肌肉分化、促進肌肉形成、促進骨分化、促進骨形成、促進脂肪分解、抗肥胖、減重、美容、改善膚質、改善肝功能之用途之方面，能夠作為製品與其他製品進行區分即可，例如可列舉於本發明之改善肝功能劑之製品之本體、包裝、說明書、宣傳物之任一者上標示出有肝功能改善功能之內容。例如所謂有肝功能改善功能之內容之標示係指：告知如在意肝功能之人、在意肝臟之健康之人等般關心肝臟運作之對象者之標示；或者標示有助於維持增進肝臟之健康，如維持肝臟之健康、輔助肝臟運作、維持健康之肝臟、維持健康之肝臟之功能、降低肝功能酶在正常範圍內偏高之數值等。又，所謂有促進脂肪分解之功能之內容之標示，係指：告知如在意肥胖之人、在意腹部周圍之人、在意體重之人、在意腹部之脂肪(內臟脂肪與皮下脂肪等)之人等般關心體脂肪之對象者之標示；或者標示有助於減少身體之脂肪，如幫助減少體重、幫助減少腹部之脂肪(內臟脂肪與皮下脂肪等)、幫助減少腰圍直徑、輔助消除肥胖、輔助減重等。 本發明之組合物安全，即便持續長期(例如3個月以上)投予(例如於1天中以上述投予量投予之情形)亦無妨。本發明之組合物較佳為如上所述持續使用。又，作為本發明之組合物之投予對象，適宜列舉有AST、ALT、γ-GTP等脫離酶之血中濃度較高之傾向之對象者，從而發揮其保護肝細胞之作用。藉由使此種對象者攝取本發明之組合物，能夠進一步提高防止肝功能降低之效果，且對於防止宿醉等亦有效。 [實施例] 以下，列舉實施例對本發明進一步詳細地進行說明。但，本發明之範圍並不限定於該等實施例。以下，於未特別事先說明之情形時，「%」表示質量%，「份」表示質量份。 [實施例1]作為實施例1之受試物質，使用質量比為鳶尾黃素(TGE)：鳶尾黃素糖苷＝1：21(糖苷之詳細成分以質量比計為TD：TGXG＝1：1.9)之粉末狀組合物。將其分別供於下述(1)〜(3)之順序之肌肉分化試驗、及下述(I)〜(V)之順序之骨分化試驗。 (肌肉分化試驗)(1)將源自小鼠橫紋肌之成肌細胞C2C12(從理化學研究所獲取)利用含10%FBS(Fetal bovine serum，胎牛血清)之DMEM(Dulbecco's minimum essential medium，杜爾伯科最低必需培養基)於5體積%CO2
培養箱中以37℃、濕潤條件進行培養直至成為特定數。其次，去除培養基，利用DPBS(Dulbecco's phosphate buffered saline，杜爾伯科磷酸緩衝液)清洗3次後，利用胰蛋白酶-乙二胺四乙酸(Trypsin-EDTA)將細胞剝離。添加新鮮之含10%FBS之DMEM，使胰蛋白酶反應停止後，將細胞收集至試管，利用離心機以800 rpm進行3分鐘離心而使細胞沈澱。以成為2×104
cells/mL之方式使細胞懸浮於新鮮之含10%FBS之DMEM中，以100 μL/well接種於96孔板中，於5體積%CO2
培養箱中以37℃、濕潤條件預培養2天。 (2)使實施例1之受試物質以TGE及TGE糖苷之總量之濃度成為40 mM之方式溶解於DMSO(Dimethyl sulfoxide，二甲基亞碸)中，將其利用含2%馬血清(HS)之DMEM稀釋至200倍，進而將其以成為特定濃度之2倍之方式利用包含0.5%DMSO之含2%HS之DMEM進行稀釋。此處所謂特定濃度，係指以TGE及TGE糖苷之總量之濃度計為25 μM。 (3)將於(1)中進行過預培養之細胞之培養基去除，添加作為分化誘導培養基之含2%HS之DMEM 50 μL、及於上述(2)中製備之含2%HS之DMEM 50 μL，進而於5%體積CO2
培養箱中以37℃、濕潤條件繼續培養24小時。另一方面，作為對照組，添加作為分化誘導培養基之含2%HS之DMEM 100 μL，以相同方式進行培養。24小時後，去除培養基，使用Rneasy mini(Qiagen公司製造)從細胞純化RNA(ribonucleic acid，核糖核酸)。利用ReverTra Ace(註冊商標)qPCR RT Master Mix with gDNA Remover(東洋紡公司製造)，由經純化之RNA合成cDNA(complementary deoxyribonucleic acid，互補脫氧核糖核酸)。使用GAPDH(glyceraldehyde-3-phosphate dehydrogenase，3-磷酸甘油醛脫氫酶)(Mm_Gapdh_3_SG QuantiTect Primer Assay，Qiagen公司製造)作為內部標準，且使用肌細胞生成素(Myogenin)(Mm_Myog_1_SG QuantiTect primer assay，Qiagen公司製造)之引子、QuantiNOVA SVBR GREEN(Qiagen公司製造)作為測定基因，利用Rotor-Gene Q(Qiagen公司製造)進行PCR(Polymerase chain reaction，聚合酶鏈反應)。PCR之結果係使用Rotor Gene Q Pure Detection(Qiagen公司製造)進行分析所得。關於藉由分析所得之基因表現量，算出將對照組(比較例1)設為100%之相對值。將結果示於圖1中。 一般於成肌細胞中，肌細胞生成素基因之表現被廣泛地用作向肌肉組織之分化誘導標記物。如圖1所示，藉由將具有特定之TGE：TGE糖苷量比之實施例1之組合物添加於分化誘導培養基中之成肌細胞中，肌細胞生成素基因表現量提高。該情況表示於添加有實施例1之組合物之成肌細胞中，向肌肉組織之分化得到促進。 (骨分化試驗)(I)：將源自小鼠頭頂之前成骨細胞MC3T3-E1細胞(從DS Pharma Biomedical公司獲取)利用含10%FBS之MEM(minimum essential medium，最低必需培養基)α培養基(不含抗壞血酸)於5體積%CO2
培養箱中以37℃、濕潤條件進行培養直至成為特定數。去除培養基，利用DPBS清洗2次後，利用胰蛋白酶-乙二胺四乙酸將細胞剝離。添加新鮮之含10%FBS之MEMα培養基，使胰蛋白酶反應停止後，將細胞收集至試管，利用離心機以800 rpm進行3分鐘離心而使細胞沈澱。以成為4×105
cells/mL之方式使細胞懸浮於新鮮之含10%FBS之MEMα培養基中，以100 μL/well接種於96孔板中，於5體積%CO2
、37℃、濕潤條件下預培養1天。 (II)：使抗壞血酸鈉與β甘油磷酸二鈉以分別成為50 μg/mL、10 mM之方式溶解於含10%FBS之MEMα培養基中，製成誘導向骨組織分化之分化誘導培養基。使實施例1之受試物質以按TGE及TGE糖苷之總量之濃度計成為20 mM之方式溶解於DMSO中，將其利用分化誘導培養基稀釋至200倍，進而將其以成為特定濃度之2倍之方式利用包含0.5%DMSO之含10%FBS之MEMα培養基進行稀釋，製成含受試物質之分化誘導培養基。此處所謂特定濃度，係指以TGE及TGE糖苷之總量之濃度計為100 μM。 (III)：將於(I)中進行過預培養之細胞之培養基去除，以100 μl/well添加(II)中製備之含受試物質之分化誘導培養基，2天或3天更換一次培養基，並於5體積%CO2
、37℃、濕潤條件下繼續培養14天。另一方面，作為對照組，將不含受試物質之分化誘導培養基以相同量添加於其他孔中，除此以外，以相同方式進行培養。 (IV)上述(III)之培養後，去除培養基，利用無血清DMEM清洗1次後，添加利用無血清DMEM培養基稀釋至30倍之細胞計數試劑盒-8(Cell Counting-Kit 8)(同仁化學公司製造)150 μL，於37℃下進行保溫直至適當顯色。利用讀板儀(ThermoScientific公司製造)測定450 nm之吸光度(A1)。(V)從(IV)之測定後之培養基去除細胞計數試劑盒-8，依據TRAP/ALP(tartrate-resistant acid phosphatase/alkaline phosphatase，抗酒石酸性磷酸酶/鹼性磷酸酶)染色試劑盒(和光純藥公司製造)之說明書，進行鹼性磷酸酶(ALP)活性測定用之染色。其次，使甘胺酸、無水氯化鎂、氯化鋅以分別成為0.1 M、1 mM、1 mM之方式溶解於超純水中，利用氫氧化鈉將pH值調整至10.4，製成甘胺酸緩衝液。使一粒4-硝基苯基磷酸二鈉鹽六水合物5 mg錠劑(Sigma Aldrich公司製造)溶解於所獲得之甘胺酸緩衝液5 ml中。將所得之液體添加至ALP染色後之各孔中150 μL。以37℃加溫30分鐘後，將上清液100 μL移至分析板(assay plate)(AGC Techno Glass公司製造)中，利用讀板儀對405 nm之吸光度(A2)進行測定。使用上述中所測得之吸光度A1及A2，藉由下述式求出ALP活性。關於由ALP活性＝A2/A1 所獲得之ALP活性之值，將對照組(比較例1)設為100%而算出相對值。將結果示於圖2中。 一般，ALP活性被廣泛地用作MC3T3-E1細胞向成骨細胞之分化誘導標記物。如圖2所示，藉由將具有特定之TGE：TGE糖苷量比之實施例1之組合物添加於分化誘導培養基中之MC3T3-E1細胞中，ALP活性提高。該情況表示於添加有實施例1之組合物之MC3T3-E1細胞中，成骨分化得到促進。 [實施例2-1〜2-8、比較例2]作為受試物質，使用將TD、TGXG及TGE以下述表1之記載進行調配所得者。表1中之TGE糖苷係指TD及TGXG之合計量。將該等實施例及比較例之受試物質供於下述(i)～(viii)之順序之(脂肪分解酶表現試驗)。
(表中，數字表示質量比) (脂肪分解酶表現試驗)利用下述方法測定激素敏感性脂肪酶(HSL)之基因表現。(i)於37℃、5體積%CO2
培養箱內，使用75 cm2
燒瓶，將供分化為脂肪細胞之小鼠成纖維(fibroblast)細胞(3T3-L1)於預培養培養基中進行培養。作為預培養培養基，使用10%FBS-DMEM。(ii)使藉由胰蛋白酶處理而浮游之細胞懸浮於10%FBS-DMEM中，以2×103
cells/well之細胞密度接種至96孔板之各孔中。將接種後之細胞於37℃、5體積%CO2
培養箱內預培養2天。(iii)去除培養基，以100 μL/well添加預先以分別包含1 μM之地塞米松、1 mM之3-異丁基-1-甲基黃嘌呤(3-Isobutyl-1-methylxanthine)、20 μg/mL之胰島素之方式製備之10%FBS-DMEM(向脂肪細胞之分化誘導培養基)，於37℃、5體積%CO2
培養箱內培養2天。(iv)從各孔去除一半培養基，更換為預先以包含20 μg/mL之胰島素之方式製備之10%FBS-DMEM(脂肪細胞分化維持培養基)，進而於37℃、5體積%CO2
培養箱內培養5天。在此期間，每隔2天將培養基之一半更換為包含胰島素之10%FBS-DMEM。(v)從各孔將培養基完全去除，以100 μL/well(TGE及TGE糖苷之總量之濃度為100 μM)添加預先以受試物質成為100 μg/mL之方式製備之10%FBS-DMEM，進而於37℃、5體積%CO2
培養箱內繼續培養48小時。(vi)將培養基完全去除，利用經冰浴冷卻之DPBS清洗2次後，以100 μL/well添加ISOGEN(NIPPON GENE公司製造)，按照使用說明書將總RNA進行純化。(vii)利用ReverTra AceR qPCR RT Master Mix with gDNA Remover，依據使用說明書，從(vi)中所獲得之總RNA合成cDNA。(viii)使用QuantiNova SYBR Green PCR試劑盒，將(vii)中所獲得之cDNA作為模板，進行RT-PCR(Reverse Transcription-Polymerase Chain Reaction，逆轉錄-聚合酶鏈反應)。作為引子，使用作為HSL基因表現用之Mm_Lipe_1_SG QuantiTect Primer Assay。內部標準使用Mm_Actb_1_SG QuantiTect Primer Assay進行Actb。關於HSL基因表現量，將以比較例2(對照組)之基因表現量為1時之實施例2-1〜2-8之相對值示於圖3中。 如圖3所示，藉由使用各實施例之受試物質，激素敏感性脂肪酶(HSL)之基因表現量大幅地高於比較例2。已知激素敏感性脂肪酶(HSL)為中性脂肪分解酶，且存在於脂肪細胞內，將甘油三酯分解為游離脂肪酸與甘油，並使游離脂肪酸釋出於血液中。因此，判明本發明之組合物藉由促進激素敏感性脂肪酶(HSL)基因表現，而有效地促進脂肪細胞中之脂肪分解。 (肝功能改善試驗)[實施例3-1～3-16以及比較例3](1)細胞培養 於37℃、5體積%CO2
培養箱內，使用75 cm2
燒瓶，藉由含10%胎牛血清(FBS)之培養基培養源自人類肝癌之細胞(HepG2，ATCC公司製造)。其次，將藉由胰蛋白酶處理而浮游之細胞以4.0×104
cells/well之細胞密度從75 cm2
燒瓶接種至96孔板之各孔中。其後，於37℃、5體積%CO2
培養箱內預培養24小時。從各孔去除培養基後，以100 μL/well添加製備成特定濃度之含受試物質之培養基，於CO2
培養箱內培養24小時。作為含受試物質之培養基中之培養基，使用無血清DMEM。作為受試物質，使用將TD、TGXG及TGE以下述表2之記載調配所得者。表2中之TGE糖苷係指TD及TGXG之合計量。作為上述特定濃度，以TD、TGXG及TGE之總量之濃度計設為400 μg/ml。比較例3為對照組(control)，使用含0.5%DMSO之無血清DMEM代替含受試物質之培養基。
＜細胞活性測定＞上述24小時培養後，去除培養基，將利用無血清DMEM稀釋至30體積倍之細胞計數試劑盒-8溶液(同仁化學製造)以每孔150 μl之方式添加至各孔中。於37℃、5體積%CO2
培養箱內進行靜置而適度地顯色後，測定450 nm下之吸光度。基於所獲得之資料，算出相對於對照組之百分率(% of control)。將由相對於對照組之百分率(% of control)＝(樣本資料(Data sample)－空白資料(Data blank))/(對照資料(Data control)－空白資料(Data blank))×100所獲得之結果示於圖4。於圖4中記載平均值及標準偏差。 根據圖4所示之結果可知，TGE及其糖苷之量比特定之鳶尾黃素類具有保護於無血清DMEM中培養之肝細胞之活性之優異作用。因此，藉由使用該質量比特定之鳶尾黃素類，能夠保護肝細胞而改善肝功能。 [實施例4]作為實施例4之受試物質，使用質量比為TGE：TGE糖苷＝1：22.19(TD：TGXG＝1：1.81)之粉末狀組合物43.14 mg(TGE及TGE糖苷之總量)。將其供於下述美容試驗。 (美容試驗)將健康正常之2名女性(平均年齡19.7歲)作為受試者。請受試者每天早晨攝取溶解於水中之實施例4之受試物質。將其持續12週。於攝取開始前、攝取開始後(4、8、12週後)，分別利用下述測定裝置測定左頰部(用直線連接外眼角與鼻翼時之中央附近)之角質層水分量、水分蒸散量、彈力。將角質層水分量之平均值示於圖5，將水分蒸散量之平均值示於圖6，將彈力之平均值示於圖7。 •角質層水分量：利用皮表角質層水分量測定裝置SKICON-200EX(I.B.S.公司製造)進行測定。該皮表角質層水分量測定裝置係將皮膚之導電率(conductance，單位：μS)作為角質層之水分量進行評價者。 •水分蒸散量：利用Tewameter TH300(Courage＋Khazaka公司製造)進行測定。 •彈力：利用皮膚黏彈力測定裝置Cutometer MPA580(Courage＋
Khazaka公司製造)進行測定。關於彈力，使用恢復彈性比率作為能夠利用作為測定器之Cutometer獲得之皮膚黏彈性值之測定參數，該恢復彈性比率係以負壓吸引測定部之皮膚一定時間，對被吸入之高度及從吸引部頂點恢復之皮膚之位移量進行分析而求出。恢復彈性比率越接近1.00，可謂皮膚之彈力性越高。該等測定係利用機器所附帶之說明書所記載之標準方法實施。 根據圖5〜圖7之結果，判明隨著具有特定之TGE：TGE糖苷量比之本發明之組合物攝取時間變長，肌膚之角質層水分量提高，水分蒸散量得到抑制，且彈力提高。 以下列舉本發明之組合物之調配例，但下述調配例並不限定本發明。 調配例1〜10：錠劑 以成為表3之比例之方式調配各成分，依據慣例進行打錠而製造調配例1〜10之錠劑(1錠250 mg)。調配例1〜10之錠劑於尤其良好地發揮提高角質層水分量、提高皮膚彈力、抑制皮膚水分蒸散等本發明之效果之方面而言優異。 [表3]
調配例11〜20：軟膠囊 藉由以成為表4之比例之方式製備軟膠囊之內容液並填充於膠囊皮膜中，而製造軟膠囊(1粒300 mg)。將膠囊皮膜液流延而製成膜，並且將內容液填充於內部進行熱密封，並使成形之軟膠囊進行乾燥而製成膠囊。調配例11〜20之軟膠囊於尤其良好地發揮提高角質層水分量、提高皮膚彈力、抑制皮膚水分蒸散等本發明之效果之方面而言優異。
調配例21〜30：粉末(顆粒劑) 依據表5，將各成分投入至Flow Coater NFLO-200型流動層造粒機(Freund Corporation(股)製造)中，於氣流下混合數分鐘。藉由對其噴霧水而進行造粒。其次，利用30目之篩子篩選所獲得之造粒物而製造顆粒劑。調配例21〜22之顆粒劑於尤其良好地發揮提高角質層水分量、提高皮膚彈力、抑制皮膚水分蒸散等本發明之效果之方面而言優異。
調配例21-22：液劑(液體飲料) 以表6之比例調配各成分而製成液體飲料。調配例31〜40之液體飲料於尤其良好地發揮提高角質層水分量、提高皮膚彈力、抑制皮膚水分蒸散等本發明之效果之方面而言優異。 Hereinafter, the present invention will be described in further detail by way of examples of the invention, but the invention is not limited thereto. In the present invention, a composition comprising a flavonoid and a flavonoid glycoside, and a composition for reducing fat, an anti-obesity composition, a composition for promoting tissue differentiation, and a combination for promoting lipolysis The composition for improving the moisture content of the stratum corneum, the skin elasticity or the skin moisture transpiration, and the composition for improving liver function are collectively referred to as "the composition of the present invention". (Iris flavin) The appendix flavin used in the present invention is of the formula C 16 H 12 O 6 It is also known as 5,7-dihydroxy-3-(4-hydroxyphenyl)-6-methoxy-4H-1-benzopyran-4-one (5,7-Dihydroxy-3- (4-hydroxyphenyl)-6-methoxy-4H-1-benzopyran-4-one) or 6 - Methoxy-5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one (6 - Methoxy-5, 7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one). Iris flavin is also described below as TGE. The chemical formula of Iris flavin is as follows. [Chemical 1] (Iris flavonoid) As the flavonoid glycoside (hereinafter also referred to as TGE glycoside), one or two hydrogens in the above TGE are substituted with sugar, and for example, the bond is selected from the group consisting of glucose and wood. One or more sugars of sugar, sorbose, galactose, parsley, and rhamnose. From the viewpoint of improving the effects of the present invention such as promoting tissue differentiation, promoting fat decomposition, improving liver function, and improving skin texture, it is preferred to bond one or more sugars selected from the group consisting of glucose and xylose to TGE. Founder. In the glycoside, the sugars are usually bonded to the hydroxyl group at the 4th position and/or the 7th position of the TGE, and in terms of obtaining the above effects more easily or the easiness of obtaining the glycoside, it is preferably 7 Hydroxyl bonder. The number of the sugars in the TGE glycoside (also referred to as the number of bonds of the sugar) is, for example, one or more. From the viewpoint of improving the above effects, the number of bonds of the sugar is preferably from one to three, more preferably 1 to 2 pieces. The term "sugar" as used herein refers to the number of monosaccharide units. As the TGE glycoside, only one type may be used, but it is preferred to combine two or more types. The TGE and TGE glycoside may be organic synthetic products in the composition of the present invention, and may also be extracted from plants or the like. The TGE and TGE glycoside may be in the form of a solid such as a powder, or may be dissolved in water or an organic solvent. The TGE and TGE glycosides may also be present in the form of such mixtures, or may be dissolved, dispersed or mixed into other materials. Examples of the glycoside in which one sugar is bonded to TGE include, for example, Tectoridin and Iris glycoside 4'-glucoside. Further, as a glycoside in which two sugars are bonded to TGE, tectorigenin-7-O-xylosylglucoside is exemplified. Here, it is said that n sugars are bonded to TGE, and a linkage of n sugars can be bonded, and the total number of sugars bonded to different parts of the saponin can be n. The so-called saponin is a glycoside formed by binding one glucose to the 7th position of TGE, and is also expressed, for example, as flavonoid 7-O-β-D-glucoside or 7-(β-D-glucopyranose oxygen). 4-(4-D-Glucopyranosyloxy-4', 5-dihydroxy-6-methoxyisoflavone), and the like. The so-called 4'-glucoside is a glycoside formed by binding one glucose to the 4th position of TGE, for example, also known as Iris flavin 4'-O-β-D-glucoside or 3-[4- (β-D-glucopyranosyloxy)phenyl]-5,7-dihydroxy-6-methoxy-4H-1-benzopyran-4-one (3-[4-(β-D) -Glucopyranosyloxy)phenyl]-5,7-dihydroxy-6-methoxy-4H-1-benzopyran-4-one). Iris flavin-7-O-xylose glucoside is a glycoside bonded to xose at the 7th position of TGE, and is then glycosidically bonded to xylose, such as 6''-O-wood. Iris glycoside (6''-O-Xylosyltectoridin). For example, iris (hereinafter also referred to as TD) has a structure of the following chemical formula. [Chemical 2] Further, for example, Iris flavin-7-O-xylose glucoside (hereinafter also referred to as TGXG) has a structure of the following chemical formula. In the formula, Glu is a glucosyl group and Xyl is a xylosyl group. [Chemical 3] In the present invention, in terms of the above-described effects, it is preferred that the TGE glycoside comprises a glycoside in which one sugar is bonded to TGE and a complex in which two sugars are bonded to TGE. When the TGE glycoside comprises a glycoside formed by binding one sugar to TGE and a complex of two sugars bonded to TGE, a glycoside and a TGE are bonded to the TGE. The quality of the glycoside formed by binding two sugars is preferably the former: the latter is 1:0.01 or more and 7.5 or less. The mass ratio of 1:0.01 or more has an advantage that the higher effect of the present invention can be obtained, and the amount of glycoside obtained by binding one sugar to TD or the like on TGE is limited to a certain amount. Further, by setting the mass ratio to 1:7.5 or less, the above effects can be further enhanced. From the above viewpoints, the ratio of the amount of glycosides in which one sugar is bonded to TGE to the glycosides in which two sugars are bonded to TGE is preferably the former: the latter is 1:0.01 or more and 5 or less More preferably, it is 1:0.1 or more and 2.5 or less. In addition, as a TGE glycoside, it is preferable to contain TD as a glycoside which binds one sugar to TGE, and contains TGXG, from the viewpoint of improving the above-mentioned effects more reliably, and the ease of obtaining glycoside. As a complex in which two sugars are bonded to TGE, the mixing ratio of TD to TGXG is preferably 0.01 or more and 7.5 or less. The blending ratio of TD and TGXG is preferably 1:0.01 or more and 5 or less, and particularly preferably 1:0.1 or more and 2.5 or less. In the present invention, the ratio of the amount of TGE to TGE glycoside is not particularly limited, and when TGE and TGE glycoside are combined at a specific ratio, particularly excellent effects can be obtained. When the mass ratio of TGE glycoside to TGE is 1:10 or more, the effect of promoting lipolysis or improving liver function is drastically improved. Further, from the viewpoint of particularly improving the effect of promoting lipolysis or improving liver function, the mass ratio of TGE to TGR glycoside is preferably 1:13 or more, and more preferably 1:16 or more. It is 1:18 or more. Further, it has been found that TGE and TGE glycosides are preferably used from the viewpoint of reducing fat, preventing obesity, promoting tissue differentiation, increasing the moisture content of the stratum corneum, improving skin elasticity, or suppressing skin moisture evapotranspiration. The mass ratio is set to the above specific ratio. The composition of the present invention can be formulated by combining the synthesized Iris flavin and the flavonoid glycoside, and can also be a shoot of the family Iridium (Belamcanda chinensis) or a genus of the genus Pueraria thomsonii, Pueraria. Extracts of plants such as lobata), Pueraria thunbergiana, etc. As an extract of plants, it is especially preferred as an extract of the flower part of the legume family. Further, it may be prepared by adding an organic synthetic product to an extract of a plant, or may be prepared by combining extracts derived from a plurality of plants, or may be prepared by combining organic synthetic products. Regarding the mass ratio of TGE to TGE glycoside, it is preferable to set the amount of TGE glycoside to be a certain value or less from the viewpoint of preventing side effects such as dermatitis, vomiting, diarrhea, and gastroenteritis caused by TGE glycoside. From this point of view, it is preferred that the mass ratio of TGE to TGE glycoside is preferably 1:500 or less, more preferably 1:250 or less, still more preferably 1:100 or less, and particularly preferably 1:50. the following. Further, from the viewpoint of improving the above-described effects, the mass ratio of TGE to TGE glycoside and the glycoside in which one sugar is bonded to TGE and the glycoside bonded to two sugars on TGE are compared with each other. Preferably, the mass ratio of the TGE to the TGE glycoside is 1:10 or more, and the mass ratio of the glycoside bonded to the TGE to the glycoside bonded to the TGE is 2: 0.01 or more and 7.5 or less. Preferred examples of the mass ratio or TGE glycoside in the combination are as described above. The measurement of the amount of TGE and TGE glycoside in the composition of the present invention can be quantitatively or qualitatively confirmed by HPLC (High Performance Liquid Chromatography). The sample for HPLC is prepared by a known method such as appropriate removal of impurities or concentration adjustment. When the composition of the present invention contains TGE and TGE glycoside at a specific ratio, it exhibits particularly excellent effects, and further improves fat reduction, anti-obesity, promotes tissue differentiation, promotes fat decomposition, increases stratum corneum moisture, and improves skin elasticity. In view of the effect of suppressing skin water evapotranspiration or improving liver function, it is particularly preferred to include an excipient. Examples of the excipient include reduced maltose, reduced palatinose, dextrin, indigestible dextrin, cellulose, polydextrose, starch, cyclodextrin, lactose, glucose, sugar, and reduction. Maltose, maltose, sorbitol, erythritol, xylitol, lactitol, mannitol. Among them, in view of improving the effects of the present invention, it is preferred to reduce maltose, reduce palatinose, dextrin, indigestible dextrin, cellulose, and polydextrose. Further, the composition of the present invention is further improved from the viewpoint of further reducing fat, anti-obesity, promoting tissue differentiation, promoting fat decomposition, increasing the moisture content of the stratum corneum, increasing skin elasticity, inhibiting skin moisture evapotranspiration, or improving liver function. It is especially good to contain oils and fats. Examples of the fats and oils include safflower oil, olive oil, rapeseed oil, palm oil, sesame oil, soybean oil, perilla oil, linseed oil, chamomile oil, rice bran oil, wheat germ oil, shea oil, and castor oil. , sunflower oil, Australian walnut oil, brown rice germ oil, camellia oil, corn oil, fish oil, coconut oil, long chain/medium long chain/short chain fatty acid triglyceride, dimercaptoglyceride, and the like Hydride, etc. Among them, safflower oil, olive oil, rapeseed oil, palm oil, sesame oil, and soybean oil are particularly preferable from the viewpoint of improving the effects of the present invention. The composition of the present invention may contain, in addition to the above, other components which are usually used within the range which does not impair the effects of the present invention. Examples of such a component include various binders, gloss agents, lubricants, stabilizers, diluents, extenders, tackifiers, emulsifiers, antioxidants, pH adjusters, coloring materials, perfumes, additives, and the like. . The content of the other components can be appropriately selected depending on the form of the composition of the present invention and the like. The composition of the present invention can be used for external or oral use. The external preparation is not particularly limited as long as it is applied to the skin, scalp or the like, and examples thereof include an ointment, a cream, a gel, a lotion, an emulsion, a dressing, and a wet compress. Such as skin external preparations, or injections and the like. Further, when the composition of the present invention is used as an oral preparation, examples thereof include a tablet, a capsule, and a powder (further, the powder of the present invention includes granules, fine particles), and a liquid. Agent, stick agent, plate form, block form, solid agent, pellet, paste, cream, capsule, gel, chewable tablet, strip, etc. . Among these, the form of a tablet, a capsule, a powder or a liquid agent is particularly preferable from the viewpoint of further improving the effect of increasing the moisture content of the stratum corneum, increasing the elasticity of the skin, or suppressing the evaporation of skin moisture. When the composition of the present invention is ingested in the form of a tablet, a capsule, a powder or a liquid, it is possible to increase the moisture content of the stratum corneum as compared with the case of ingesting it in other forms such as a cream or a cream or a gel. Achieve higher results in terms of improving skin elasticity or inhibiting skin moisture evapotranspiration. The reason for this is not clear, but it is considered that the main reason is that the psychological effects on the ingestors are different depending on the form of the composition; or the in vivo absorption rates of TGE and TGE glycosides are different depending on the shape. As a specific example of the case where the composition of the present invention is used as an oral preparation, a supplement may be exemplified; a food additive; a container-packed beverage filled in a PET bottle, a can, a bottle, or the like; (hot water), milk, juice, etc. These are preferred in terms of being easy to eat and eat when eating, and being able to improve palatability. In general, in the case where the composition of the present invention is a tablet or a capsule, it is preferable that in the solid matter component, the active ingredient contains a solid matter from the viewpoint of the above effects brought about by the present invention. The TGE of 2.0 to 0.001% by mass of the total component is more preferably 1.0 to 0.01% by mass, still more preferably 0.5 to 0.025% by mass. In addition, when the total amount of the TGE and the TGE glycoside is, for example, 0.5% by mass or more, particularly 1% by mass or more, based on the solid content of the composition of the present invention, the above effects are further excellent, which is preferable. The composition of the present invention as a tablet or a capsule may, for example, be a pharmaceutical or a supplement. In the case where the composition of the present invention is a liquid preparation, it is preferable that the active ingredient contains 0.00001 to 0.5% by mass of the total amount of the active ingredient in the liquid preparation. More preferably, TGE is 0.00005 to 0.1% by mass, and more preferably 0.0001 to 0.05% by mass. In addition, the total amount of the TGE and the TGE glycoside is preferably 0.0001% by mass or more, particularly preferably 0.1% by mass or more, based on the solid content of the composition of the present invention. The composition of the present invention as a liquid agent may, for example, be a packaged beverage or the like. Further, in the case where the composition of the present invention is a powder or granule, it is preferable that in the solid matter component, the active ingredient contains a solid matter from the viewpoint of the above-described respective effects brought about by the present invention. The TGE of 0.0001 to 2.5% by mass of the total amount of the component is more preferably 0.001 to 2.0% by mass, still more preferably 0.005 to 1.5% by mass. In addition, the total amount of the TGE and the TGE glycoside is preferably 0.001% by mass or more, and particularly preferably 0.01% by mass or more, based on the solid content of the composition of the present invention. As a composition of the present invention as a powder, an instant powdered beverage or the like can be given. When the composition of the present invention is orally ingested, the oral administration amount thereof is preferably about 5 mg or more and 200 mg or less per day of the adult, based on the total dry weight of the TGE and TGE glycoside. It is 10 mg or more and 100 mg or less. Further, the first intake of the composition of the present invention is preferably about 15 mg or more and 50 mg or less per day of the adult, based on the total dry weight of the TGE and TGE glycoside. The composition of the present invention can be contained in one container for one day or separately in a plurality of containers of, for example, two to three, so that the intake amount per day becomes the above-mentioned intake amount. Specific examples of the use form of the composition of the present invention include pharmaceuticals (including quasi-drugs), cosmetics, general foods, nutritious functional foods, and performance-specific foods that are recognized by specific institutions and functional labels. So-called healthy foods such as food. In the application form of the composition of the present invention, examples of the food include carbonated drinks, nutritional drinks, fruit drinks, lactic acid drinks, smoothies, and green juice; and frozen desserts such as ice cream, snow cheese, and shaved ice: Soba, udon noodles, vermicelli, Chinese noodles, instant noodles, etc.; sugar, candy, chewing gum, chocolate, molded snacks, snacks, biscuits, jellies, jams, cream, baked pastries, bread, etc.; Cakes, ham, sausages and other aquatic products, processed foods for livestock; processed dairy products, yoghurt, yogurt and other dairy products; salad oil, tempura oil, margarine, mayonnaise, shortening, thick cream, sauce and other fats and processing Food; sauces, soy sauce and other seasonings; curry, stew, chicken and egg rice, porridge, chowder, Chinese rice bowl, pork ribs rice, fried shrimp rice, beef rice, diced rice, egg rice, Oden , Mapo tofu, dumplings, siu mai, fried meat patties, meatballs, various sauces, various soups and other sterilized bagged foods. The composition of the present invention can be ingested not only economically and safely, but also according to the description of the following examples. The composition of the present invention can be promoted from striated muscle by ingesting it by containing TGE and TGE glycoside. Muscle cells undergo muscle differentiation and, in addition, promote differentiation of pre-osteoblasts into osteoblasts, thereby promoting bone differentiation. Further, the composition of the present invention can obtain an excellent lipolytic action by ingesting it by containing TGE and TGE glycoside. For example, it is clear from the description of the following examples that the expression of the gene of the enzyme which decomposes body fat can be promoted by ingesting TGE and TGE glycoside, and the decomposition of body fat can be promoted. Further, in the present invention, TGE and TGE glycosides are effective for improving the function of improving liver function. Specifically, it is clear from the description of the following examples that TGE and TGE glycosides can increase the activity (enzymatic activity) of hepatocytes cultured in a serum-free medium, and various stresses in the hepatocytes become induced, thereby causing easy cell production. Death and other issues. That is, TGE and TGE glycosides inhibit the activity of hepatocytes, ie, protect liver cells. As described above, TGE and TGE glycosides can protect liver cells, thereby preventing damage to liver cells, maintaining or enhancing the activity of liver cells and improving liver function. In particular, it is expected to prevent hepatic cell damage by protecting liver cells from various stresses, thereby inhibiting aspartate transaminase (ALT), alanine transaminase (ALT), γ- in hepatocytes. Glutamate transpeptidase (γ-glutamyltransferase, γ-GTP) is transferred to the blood. Further, by ingesting TGE and TGE glycosides, it is possible to obtain an effect of increasing the water content of the stratum corneum of the skin, an effect of improving skin elasticity, and suppressing skin moisture evapotranspiration. These effects of improving the skin are manifested by the continuous ingestion of the composition of the present invention, for example, within 4 weeks after the start of oral ingestion, and further by continuous ingestion for 8 weeks, especially for 12 weeks. Significantly expressed by ingestion. The term "sustained intake" as used herein refers to a state in which at least one ingestion is continued for one to three days, for example. The composition of the present invention can be used as a composition for promoting muscle differentiation, a composition for promoting muscle formation, a composition for promoting bone differentiation, a composition for promoting bone formation, a composition for promoting lipolysis, and a combination for promoting lipid metabolism. Composition for reducing fat, composition for anti-obesity, composition for weight loss, cosmetic composition, composition for increasing skin moisture, composition for inhibiting moisture evaporation, composition for improving skin elasticity, and skin-enhancing composition In addition, it can also be used as a liver function improving agent or liver for preventing or inhibiting the action of hepatocyte-derived enzyme efflux, preventing or inhibiting liver cell damage, protecting liver cells, and protecting or improving liver function. The functional improvement composition can be used for the treatment or prevention of liver function damage such as viral hepatitis, drug-induced liver damage, autoimmune hepatitis, primary biliary cirrhosis, and Budd-Chiari syndrome. As described above, the composition of the present invention can be used for preventing damage other than diseases related to drinking such as hangover. Further, the composition of the present invention is used for the purpose of promoting muscle differentiation, promoting muscle formation, promoting bone differentiation, promoting bone formation, promoting fat decomposition, anti-obesity, weight loss, beauty, skin quality, and liver function improvement. The product can be distinguished from other products, and for example, the liver function improving function can be listed on any of the main body, packaging, instructions, and advertisements of the product for improving liver function of the present invention. For example, the labeling of the content of the function of improving liver function refers to: indicating the person who cares about the operation of the liver, such as a person who cares about liver function, a person who cares about the health of the liver, or the label helps to maintain the health of the liver, Such as maintaining the health of the liver, assisting the liver, maintaining a healthy liver, maintaining the function of a healthy liver, and lowering the value of liver function enzymes in the normal range. In addition, the labeling of the function of promoting the function of fat decomposition means that the person who cares about obesity, the person around the abdomen, the person who cares about the weight, the person who cares about the fat of the abdomen (visceral fat and subcutaneous fat, etc.) The label of the person who cares about body fat; or the label helps to reduce the body's fat, such as helping to reduce weight, helping to reduce abdominal fat (visceral fat and subcutaneous fat, etc.), helping to reduce waist circumference, assisting in eliminating obesity, and assisting in reducing Wait a minute. The composition of the present invention is safe, even if it is administered for a long period of time (for example, three months or more) (for example, in the case of administration of the above administration amount in one day). The compositions of the present invention are preferably used as described above. In addition, as a target of administration of the composition of the present invention, a target of a high concentration of a detachment enzyme such as AST, ALT or γ-GTP is preferred, and the action of protecting liver cells is exhibited. By ingesting the composition of the present invention, the subject can further improve the effect of preventing liver function from being lowered, and is also effective for preventing hangover and the like. [Examples] Hereinafter, the present invention will be described in further detail by way of examples. However, the scope of the invention is not limited to the embodiments. Hereinafter, in the case where it is not specifically described in advance, "%" represents mass%, and "part" represents mass parts. [Example 1] As a test substance of Example 1, the mass ratio of use was Irisin (TGE): Iris flavonoid = 1:21 (the detailed composition of glycoside was TD by mass ratio: TGXG = 1:1.9) a powdered composition. These were separately supplied to the muscle differentiation test in the order of (1) to (3) below, and the bone differentiation test in the order of (I) to (V) below. (Muscle differentiation test) (1) D2 derived from mouse striated muscle myoblast C2C12 (obtained from the Institute of Physical and Chemical Research) using DMEM containing 10% FBS (Fetal bovine serum, fetal bovine serum) (Dulbecco's minimum essential medium, Du Erbeco minimum essential medium) at 5 vol% CO 2 The culture was carried out at 37 ° C in a humidified condition until it became a specific number. Next, the medium was removed, washed three times with DPBS (Dulbecco's phosphate buffered saline), and then the cells were detached by trypsin-ethylenediaminetetraacetic acid (Trypsin-EDTA). Fresh DMEM containing 10% FBS was added, and after the trypsin reaction was stopped, the cells were collected into a test tube, and the cells were pelleted by centrifugation at 800 rpm for 3 minutes using a centrifuge. To become 2×10 4 Cells/mL were suspended in fresh DMEM containing 10% FBS and seeded in 96-well plates at 100 μL/well at 5 vol% CO 2 The cells were precultured for 2 days at 37 ° C under humid conditions in an incubator. (2) The test substance of Example 1 was dissolved in DMSO (Dimethyl sulfoxide, dimethyl sulfoxide) so that the concentration of the total amount of TGE and TGE glycoside was 40 mM, and it was made to contain 2% horse serum ( The DMEM of HS) was diluted to 200-fold and further diluted with DMEM containing 2% HS containing 0.5% DMSO in such a manner as to be twice the specific concentration. The specific concentration referred to herein means 25 μM in terms of the total concentration of TGE and TGE glycoside. (3) The medium of the pre-cultured cells in (1) was removed, 50 μL of DMEM containing 2% HS as a differentiation induction medium, and DMEM 50 containing 2% of HS prepared in the above (2) were added. μL, and further 5% volume CO 2 Incubation was continued for 24 hours at 37 ° C in a humidified condition in an incubator. On the other hand, as a control group, 100 μL of DMEM containing 2% HS as a differentiation induction medium was added, and culture was carried out in the same manner. After 24 hours, the medium was removed, and RNA (ribonucleic acid, ribonucleic acid) was purified from the cells using Rneasy mini (manufactured by Qiagen). A cDNA (complementary deoxyribonucleic acid) was synthesized from purified RNA using ReverTra Ace (registered trademark) qPCR RT Master Mix with gDNA Remover (manufactured by Toyobo Co., Ltd.). GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used as an internal standard, and Myogenin was used (Mm_Myog_1_SG QuantiTect primer assay, Qiagen As a measurement gene, a primer (Quantienase chain reaction, PCR) was used as a measurement gene by Rotor-Gene Q (manufactured by Qiagen Co., Ltd.). The results of the PCR were analyzed using Rotor Gene Q Pure Detection (manufactured by Qiagen). The relative value of the control group (Comparative Example 1) was set to 100% by the amount of gene expression obtained by the analysis. The results are shown in Fig. 1. Generally, in myoblasts, the expression of myogenin gene is widely used as a differentiation-inducing marker to muscle tissue. As shown in Fig. 1, the amount of myogenin gene expression was increased by adding the composition of Example 1 having a specific TGE:TGE glycoside ratio to the myoblasts in the differentiation induction medium. This case indicates that differentiation into muscle tissue is promoted in myoblasts to which the composition of Example 1 is added. (Bone Differentiation Test) (I): Osteoblast MC3T3-E1 cells (obtained from DS Pharma Biomedical Co., Ltd.) derived from the head of the mouse were treated with MEM (minimum essential medium) α medium containing 10% FBS ( Contains no ascorbic acid) at 5 vol% CO 2 The culture was carried out at 37 ° C in a humidified condition until it became a specific number. After the medium was removed and washed twice with DPBS, the cells were detached by trypsin-ethylenediaminetetraacetic acid. Fresh MEMα medium containing 10% FBS was added, and after the trypsin reaction was stopped, the cells were collected into a test tube, and centrifuged at 800 rpm for 3 minutes to precipitate cells. To become 4×10 5 In the cells/mL format, the cells were suspended in fresh MEMα medium containing 10% FBS, and seeded in a 96-well plate at 100 μL/well at 5 vol% CO. 2 Pre-culture for 1 day at 37 ° C under humid conditions. (II): Sodium ascorbate and disodium β-glycerophosphate were dissolved in MEMα medium containing 10% FBS so as to be 50 μg/mL and 10 mM, respectively, to prepare a differentiation induction medium for inducing differentiation into bone tissue. The test substance of Example 1 was dissolved in DMSO so that the concentration of TGE and TGE glycoside was 20 mM, and it was diluted to 200-fold by the differentiation induction medium, and further, it was made into a specific concentration. The method of doubling was diluted with MEMα medium containing 10% FBS containing 0.5% DMSO to prepare a differentiation induction medium containing the test substance. The specific concentration referred to herein means 100 μM in terms of the total concentration of TGE and TGE glycoside. (III): The medium of the pre-cultured cells in (I) is removed, and the differentiation induction medium containing the test substance prepared in (II) is added at 100 μl/well, and the medium is changed once every 2 days or 3 days. And at 5 vol% CO 2 The culture was continued for 14 days at 37 ° C under humid conditions. On the other hand, as a control group, the differentiation induction medium containing no test substance was added to the other wells in the same amount, and the culture was carried out in the same manner. (IV) After the culture of the above (III), the medium was removed, and the cells were washed once with serum-free DMEM, and then added to a Cell Counting Kit-8 (Cell Counting-Kit 8) diluted with serum-free DMEM medium (Cell Counting-Kit 8) (Tongren Chemical Co., Ltd.) 150 μL of the company was incubated at 37 ° C until proper color development. The absorbance at 450 nm (A1) was measured using a plate reader (manufactured by Thermo Scientific). (V) Cell Counting Kit-8 was removed from the medium after the determination of (IV), according to TRAP/ALP (tartrate-resistant acid phosphatase/alkaline phosphatase, anti-tartaric acid phosphatase/alkaline phosphatase) staining kit (and The instructions for the measurement of alkaline phosphatase (ALP) activity were carried out in the instructions of Wako Pure Chemical Industries, Ltd. Next, glycine acid, anhydrous magnesium chloride, and zinc chloride were dissolved in ultrapure water so as to be 0.1 M, 1 mM, and 1 mM, respectively, and the pH was adjusted to 10.4 with sodium hydroxide to prepare a glycine buffer. liquid. One 5-nitrophenyl phosphate disodium salt hexahydrate 5 mg tablet (manufactured by Sigma Aldrich Co., Ltd.) was dissolved in 5 ml of the obtained glycine buffer. The resulting liquid was added to 150 μL of each well after ALP staining. After warming at 37 ° C for 30 minutes, 100 μL of the supernatant was transferred to an assay plate (manufactured by AGC Techno Glass Co., Ltd.), and the absorbance at 405 nm (A2) was measured using a plate reader. The ALP activity was determined by the following formula using the absorbances A1 and A2 measured above. Regarding the value of the ALP activity obtained from ALP activity = A2/A1, the control group (Comparative Example 1) was set to 100%, and the relative value was calculated. The results are shown in Figure 2. In general, ALP activity is widely used as a differentiation-inducing marker for MC3T3-E1 cells to osteoblasts. As shown in Fig. 2, ALP activity was improved by adding a composition having the specific TGE:TGE glycoside ratio to the MC3T3-E1 cells in the differentiation induction medium. This indicates that osteogenic differentiation was promoted in the MC3T3-E1 cells to which the composition of Example 1 was added. [Examples 2-1 to 2-8, Comparative Example 2] As the test substance, those obtained by blending TD, TGXG, and TGE in the following Table 1 were used. The TGE glycoside in Table 1 refers to the total amount of TD and TGXG. The test substances of the examples and the comparative examples were supplied to the following (i) to (viii) (lipolytic enzyme expression test). (In the table, the number indicates the mass ratio) (Lipolytic enzyme performance test) The gene expression of hormone-sensitive lipase (HSL) was measured by the following method. (i) at 37 ° C, 5 vol% CO 2 In the incubator, use 75 cm 2 In a flask, mouse fibroblast cells (3T3-L1) for differentiation into adipocytes were cultured in a preculture medium. As a preculture medium, 10% FBS-DMEM was used. (ii) suspending cells floating by trypsin treatment in 10% FBS-DMEM at 2×10 3 The cell density of cells/well was seeded into each well of a 96-well plate. The cells after inoculation were at 37 ° C, 5 vol% CO 2 Pre-culture in the incubator for 2 days. (iii) Remove the medium and add 100 μL/well to contain 1 μM dexamethasone, 1 mM 3-Isobutyl-1-methylxanthine, 20 μg, respectively. 10% FBS-DMEM (differentiation induction medium to adipocytes) prepared in the form of /mL insulin, at 37 ° C, 5 vol% CO 2 The culture was carried out for 2 days in an incubator. (iv) Remove half of the medium from each well and replace with 10% FBS-DMEM (adipocyte differentiation maintenance medium) prepared in advance containing 20 μg/mL of insulin, and further at 37 ° C, 5 vol % CO 2 Incubate in an incubator for 5 days. During this time, one half of the medium was replaced with 10% FBS-DMEM containing insulin every 2 days. (v) Completely remove the medium from each well, and add 10% FBS-DMEM prepared in advance to a test substance of 100 μg/mL at a concentration of 100 μL/well (100 μM of total TGE and TGE glycoside). And further at 37 ° C, 5 vol% CO 2 The culture was continued for 48 hours in the incubator. (vi) The medium was completely removed, and the mixture was washed twice with DPBS cooled in an ice bath, and then ISOGEN (manufactured by NIPPON GENE Co., Ltd.) was added at 100 μL/well, and total RNA was purified according to the instruction manual. (vii) cDNA was synthesized from total RNA obtained in (vi) using ReverTra AceR qPCR RT Master Mix with gDNA Remover according to the instruction manual. (viii) RT-PCR (Reverse Transcription-Polymerase Chain Reaction) was carried out using the QuantiNova SYBR Green PCR kit using the cDNA obtained in (vii) as a template. As the primer, the Mm_Lipe_1_SG QuantiTect Primer Assay for expression of the HSL gene was used. The internal standard uses the Mm_Actb_1_SG QuantiTect Primer Assay for Actb. Regarding the expression amount of the HSL gene, the relative values of Examples 2-1 to 2-8 when the gene expression amount of Comparative Example 2 (control group) was 1 are shown in Fig. 3 . As shown in FIG. 3, the gene expression amount of hormone-sensitive lipase (HSL) was significantly higher than that of Comparative Example 2 by using the test substances of the respective examples. It is known that hormone sensitive lipase (HSL) is a neutral lipolytic enzyme and is present in fat cells, which decomposes triglycerides into free fatty acids and glycerol, and releases free fatty acids into the blood. Therefore, it has been found that the composition of the present invention effectively promotes lipolysis in fat cells by promoting hormone-sensitive lipase (HSL) gene expression. (Hepatic function improvement test) [Examples 3-1 to 3-16 and Comparative Example 3] (1) Cell culture at 37 ° C, 5 vol% CO 2 In the incubator, use 75 cm 2 The flask was cultured with human liver cancer-derived cells (HepG2, manufactured by ATCC) in a medium containing 10% fetal calf serum (FBS). Secondly, the cells that are floated by trypsin treatment are 4.0×10 4 Cell/well cell density from 75 cm 2 The flask was inoculated into each well of a 96-well plate. Thereafter, at 37 ° C, 5 vol% CO 2 Pre-culture in the incubator for 24 hours. After removing the medium from each well, a medium containing a test substance at a specific concentration was added at 100 μL/well to CO. 2 Incubate in an incubator for 24 hours. Serum-free DMEM was used as the medium in the medium containing the test substance. As the test substance, those obtained by blending TD, TGXG, and TGE in the following Table 2 were used. The TGE glycoside in Table 2 refers to the total amount of TD and TGXG. The specific concentration was set to 400 μg/ml in terms of the total concentration of TD, TGXG and TGE. Comparative Example 3 was a control, and serum-free DMEM containing 0.5% DMSO was used instead of the medium containing the test substance. <Cell activity assay> After the above-mentioned 24 hours of culture, the medium was removed, and a cell counting kit-8 solution (manufactured by Toray Chemical Co., Ltd.) diluted to 30-fold by volume with serum-free DMEM was added to each well at 150 μl per well. At 37 ° C, 5 vol% CO 2 After standing in the incubator and moderately developing color, the absorbance at 450 nm was measured. Based on the obtained data, the percentage relative to the control group (% of control) was calculated. The result obtained from the percentage of control = (Data sample - Data blank) / (Data control - Data blank) × 100 Shown in Figure 4. The average value and standard deviation are shown in FIG. From the results shown in Fig. 4, it was found that the amount of TGE and its glycoside had an excellent effect of protecting the activity of hepatocytes cultured in serum-free DMEM than the specific flavonoids. Therefore, by using the mass ratio specific appendix flavin, liver cells can be protected and liver function can be improved. [Example 4] As a test substance of Example 4, a powder composition of 43.14 mg (TGE and TGE glycoside) having a mass ratio of TGE:TGE glycoside = 1:22.19 (TD: TGXG = 1:1.81) was used. ). It was supplied to the following cosmetic test. (Beauty test) Two women (average age 19.7 years old) with normal health were used as subjects. Subjects were asked to take the test substance of Example 4 dissolved in water every morning. It will last for 12 weeks. Before the start of ingestion and after the start of ingestion (after 4, 8 and 12 weeks), the water content of the stratum corneum and the amount of water evapotranspiration in the left cheek (near the center of the outer corner of the eye and the nose) were measured by the following measuring device. ,elastic force. The average value of the moisture content of the stratum corneum is shown in Fig. 5, the average value of the moisture evaporation amount is shown in Fig. 6, and the average value of the elastic force is shown in Fig. 7. • Water content of the stratum corneum: The measurement was performed using a skin surface layer moisture measuring device SKICON-200EX (manufactured by IBS). The skin cuticle moisture content measuring device evaluates the skin conductance (unit: μS) as the moisture content of the stratum corneum. • Moisture evapotranspiration: Measurement was carried out using a Tewameter TH300 (manufactured by Courage+Khazaka Co., Ltd.). • Elasticity: Using the skin viscoelasticity measuring device Cutometer MPA580 (Courage + The measurement was carried out by Khazaka Co., Ltd.). Regarding the elastic force, the recovery elastic ratio is used as a measurement parameter of the skin viscoelasticity value which can be obtained by using a Cutometer as a measuring device, which absorbs the skin of the measuring portion with a negative pressure for a certain period of time, the height to be inhaled and the suction portion. The amount of displacement of the skin of the vertex recovery is obtained by analyzing. The closer the recovery elastic ratio is to 1.00, the higher the elasticity of the skin. These measurements were carried out using standard methods described in the instructions attached to the machine. From the results of Fig. 5 to Fig. 7, it was found that as the composition of the present invention having a specific TGE:TGE glycoside ratio was longer, the water content of the stratum corneum of the skin was increased, the amount of water evapotranspiration was suppressed, and the elastic force was improved. The formulation examples of the composition of the present invention are listed below, but the following formulation examples do not limit the present invention. Formulation Examples 1 to 10: The tablets were formulated so as to have a ratio of Table 3, and tableting was carried out in accordance with the usual practice to prepare tablets (1 tablet 250 mg) of Formulation Examples 1 to 10. The lozenges of the blending examples 1 to 10 are excellent in that the effects of the present invention such as an increase in the moisture content of the stratum corneum, an increase in skin elasticity, and suppression of skin moisture evapotranspiration are particularly excellent. [table 3] Formulation Examples 11 to 20: Soft capsules A soft capsule (one tablet of 300 mg) was prepared by preparing a content liquid of a soft capsule in a ratio of Table 4 and filling it in a capsule film. The capsule film solution is cast to form a film, and the content liquid is filled inside to be heat-sealed, and the formed soft capsule is dried to obtain a capsule. The soft capsules of the blending examples 11 to 20 are excellent in that the effects of the present invention such as an increase in the moisture content of the stratum corneum, an increase in skin elasticity, and suppression of skin moisture evapotranspiration are particularly excellent. Preparation Examples 21 to 30: Powder (granules) According to Table 5, each component was placed in a Flow Coater NFLO-200 fluidized bed granulator (manufactured by Freund Corporation), and mixed under air flow for several minutes. Granulation is carried out by spraying water thereon. Next, the obtained granules were sieved using a 30-mesh sieve to produce granules. The granules of the blending examples 21 to 22 are excellent in that the effects of the present invention such as an increase in the moisture content of the stratum corneum, an increase in skin elasticity, and suppression of skin moisture evapotranspiration are particularly excellent. Formulation Example 21-22: Liquid (Liquid Beverage) Each component was prepared in the ratio of Table 6 to prepare a liquid beverage. The liquid beverages of the blending examples 31 to 40 are excellent in that the effects of the present invention such as an increase in the moisture content of the stratum corneum, an increase in skin elasticity, and suppression of skin moisture evapotranspiration are particularly excellent.